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Abstract: Chronic hepatitis C (CHC) patients often stop pursuing interferon-alfa and ribavi-
rin (IFN-alfa/RBV) treatment because of the high cost and associated adverse effects. It is 
highly desirable, both clinically and economically, to establish tools to distinguish respond-
ers from nonresponders and to predict possible outcomes of the IFN-alfa/RBV treatments. 
Single nucleotide polymorphisms (SNPs) can be used to understand the relationship between 
genetic inheritance and IFN-alfa/RBV therapeutic response. The aim in this study was to 
establish a predictive model based on a pharmacogenomic approach. Our study population 
comprised Taiwanese patients with CHC who were recruited from multiple sites in Taiwan. 
The genotyping data was generated in the high-throughput genomics lab of Vita Genomics, 
Inc. With the wrapper-based feature selection approach, we employed multilayer feedforward 
neural network (MFNN) and logistic regression as a basis for comparisons. Our data revealed 
that the MFNN models were superior to the logistic regression model. The MFNN approach 
provides an efficient way to develop a tool for distinguishing responders from nonresponders 
prior to treatments. Our preliminary results demonstrated that the MFNN algorithm is effective 
for deriving models for pharmacogenomics studies and for providing the link from clinical 
factors such as SNPs to the responsiveness of IFN-alfa/RBV in clinical association studies in 
pharmacogenomics.
Keywords: chronic hepatitis C, artificial neural networks, interferon, pharmacogenomics, 
ribavirin, single nucleotide polymorphisms
Chronic hepatitis C (CHC) affects more than 170 million individuals worldwide and is 
a chronic liver disease characterized by infection with the hepatitis C virus persisting 
for more than six months.1,2 Combination therapy with interferon-alfa and ribavirin 
(IFN-alfa/RBV) has been the preferred treatment for CHC patients,1,2 however, due 
to the high cost and significant adverse reactions, patients often stop pursuing the 
treatment.1,2 Consequently, it would be highly desirable to establish models that dis-
tinguish responders from nonresponders (NRs) and predict the possible outcome of 
the IFN-alfa/RBV treatment.3,4
The efficacy of IFN-alfa/RBV is likely influenced by the combined effects of a 
number of genetic variants.3–5 Accumulating evidence reveals that single nucleotide 
polymorphisms (SNPs) could be used as genetic markers to predict IFN-alfa/RBV treat-
ment outcome in CHC.3–5 Results of several studies6–8 in different populations support 
the implication that the effects of IFN-alfa/RBV are associated with genetic variants. 
In addition, the genetic differences have been analyzed and found to be associated 
with IFN-alfa/RBV responses using a multiple logistic regression method.3Advances and Applications in Bioinformatics and Chemistry 2010:3 submit your manuscript | www.dovepress.com
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Artificial neural network (ANN) algorithms are generally 
adopted for complex classification applications because of 
the advantages of ANN algorithms, such as nonlinearity, 
fault tolerance, universality, and real-time operation.9,10 ANN 
algorithms have been employed to build a prediction model 
for the drug efficacy of IFN-alfa/RBV in CHC patients based 
on SNPs and other clinical factors.4,5 Moreover, the possible 
nonlinear relationships between genetic variants and antide-
pressant response have been explored using ANN algorithms 
in pharmacogenomics studies.11,12
The previous researchers3–5 mainly reported modeling 
IFN-alfa/RBV treatment response by using logistic regression 
or ANN methods without feature selection. In this work, we 
extended the previous research and applied both ANN algo-
rithms and logistic regression with feature selection to predict 
IFN-alfa/RBV treatment outcomes using genetic factors.
Materials and methods
Patients
The cohort of 523 CHC patients was original to the previous 
study by Lin and colleagues4 and is described in detail in the 
latter research.4 Briefly, blood samples were collected from 
523 CHC patients at National Taiwan University Hospital, 
Kaohsiung Medical University Hospital, Kaohsiung Chang-
Gung Memorial Hospital, and Tri-Service General Hospital 
in Taiwan from 2002 to 2004. Patients whose serum HCV 
RNA became negative and lasted for more than 6 months 
after the end of treatment were defined as sustained virologic 
responders (SVRs) of the treatment. Those who still remained 
viremic were defined as NRs. There were 523 participants, 
including 350 SVRs and 173 NRs.4 We further converted the 
clinical diagnostic data into numerical forms, that is, 1 for 
“SVR” and 0 for “NR”, respectively.
genotyping
Genomic DNAs were extracted from each of the blood 
samples by using QIAamp DNA Blood kit according to the 
manufacturer’s instructions as described in detail elsewhere.4,5 
The quality of the extracted genomic DNAs was checked 
by agarose gel electrophoresis analysis and stored at -80°C 
until use.
Furthermore, genomic DNA was amplified using a 
  commercially available INFor SNP detection kit (Vita 
Genomics, Inc., Taiwan) according to the manufacturer’s 
instructions as described in detail elsewhere.4,5 More specifi-
cally, fragments of target genes were amplified by the PCR 
reaction. Amplification was carried out using 2700 PCR 
machines (ABI, Foster City, USA) and the amplified products 
were purified by membrane ultra-filtration with MultiScreen 
PCR plate (Millipore, Billerica, USA) according to the 
manufacturer’s instructions. After the sequencing reaction, 
the reaction product was loaded onto an ABI 3700 Capillary 
Sequencer. Finally, the genotype of each tested individual 
was determined by computer software and was confirmed 
manually.
genetic factors
In the present study, we only focused on the 24 SNPs as 
described in the previous study.13 The rationale for selecting 
these SNPs is described in detail elsewhere.3–5 The SNPs 
genetic markers of the participants were generated at the 
high-throughput genomics lab of Vita Genomics, Inc.
Because there are three genotypes per locus, each SNP 
was coded as 0 for homozygote of the major allele, 1 for 
heterozygote, and 2 for homozygote of the minor allele, 
respectively.
Artificial neural network algorithms
In this study, we used two families of classification algo-
rithms, including multilayer feedforward neural network 
(MFNN) and logistic regression as a basis for comparisons. 
An MFNN is one type of ANN models where connections 
between the units do not form a directed cycle.14 These clas-
sifiers were performed using the Waikato Environment for 
Knowledge Analysis (WEKA) software.15
From an algorithmic point of view, the underlying process 
of this MFNN can be divided into the retrieving and learn-
ing phases.4,5 Let us assume an L-layer feedforward neural 
network (with Nl units at the l-th layer). In the retrieving 
phase, the MFNN iterates through all the layers to produce 
the retrieval response {ai(L), i = 1, …, NL} at the output layer 
based on the inputs of test patterns {ai(0), i = 1, …, N0}, the 
known weights wij of the network, and the nonlinear activa-
tion function fi (for example, sigmoid function). In the learn-
ing phase of this MFNN, the back-propagation algorithm16 
is employed for the learning scheme. The back-propagation 
algorithm is a simple gradient descent approach. The weight 
updating process adopts the mechanism of back-propagated 
corrective signals from the output layer for the hidden layers. 
The goal is to iteratively select a set of weights wij(l) for all 
layers such that the squared error function E can be mini-
mized by giving a pair of input training patterns {ai(0), i = 1, 
…, N0} and target training patterns {tj, j = 1, …, NL}.
Mathematically, the iterative gradient descent formulation 
for updating each specific weight wij (l) can be expressed as 
the following equationAdvances and Applications in Bioinformatics and Chemistry 2010:3 submit your manuscript | www.dovepress.com
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where η is the learning rate and ∂E/∂wij(l ) can be effec-
tively calculated through a numerical chain rule by back-
propagating the error signal from the output layer to the 
input layer.4
On the other hand, an MFNN is a spatial and iterative 
neural network which has several layers of hidden neuron 
units between the input and output neuron layers from a struc-
tural point of view.4,5 The basic function of each neuron is the 
linear basis function, and a nondecreasing and differentiable 
sigmoid function models the activation.16 In our approach, 
we employed an MFNN for modeling the responsiveness of 
IFN-alfa/RBV . Inputs contain the information about clinical 
factors such as SNPs for the CHC patients. Outputs contain 
the information about the responsiveness of IFN-alfa/RBV .
In summary, the MFNN is trained first by repeatedly 
providing input-output training pairs and executing the back-
propagation learning algorithm.4,5 After this training process, 
the MFNN is tested by giving the inputs of testing data (that 
is, clinical factors) to the network. The forward propagation of 
the MFNN furnishes us with the responsiveness of IFN-alfa/
RBV for a particular patient, indicating a means of inference 
from cause to effect.
Here, we used WEKA’s default parameters, such as the 
learning rate = 0.3 and the momentum variable = 0.2.
Feature selection
To identify a subset of clinical factors that maximize the 
performance of the prediction model, we employed the 
wrapper-based feature selection approach, where the feature 
selection algorithm acts as a wrapper around the classification 
algorithm.17 The wrapper-based approach conducts best-first 
search for a good subset and uses the classification algorithm 
itself as part of the function for evaluating feature subsets.18 
The best-first search starts with an empty set of clinical 
factors and searches forward to choose possible subsets of 
clinical factors by greedy hill-climbing augmented with a 
backtracking technique.15 As shown in Figure 1, we applied 
MFNN and logistic regression with the wrapper-based 
approach, respectively.
evaluation of the predictive performance
To investigate the generalization of the prediction models 
produced by the above algorithms, we utilized the repeated 
10-fold cross-validation method.17 First, the whole dataset 
was randomly divided into 10 distinct parts. Second, the 
model was trained by nine-tenths of the data and tested by 
the remaining tenth of data to estimate the predictive perfor-
mance. Then, the above procedure was repeated nine more 
times by leaving out a different tenth of data as testing data 
and different nine-tenths of the data as training data. Finally, 
the average estimate over all runs was reported by running 
the above regular 10-fold cross-validation for 100 times with 
different splits of data.
To measure the performance of prediction models, we 
defined the accuracy as the proportion of true predicted 
participants of all tested participants.4,5 In addition, we used 
the receiver operating characteristic (ROC) methodology 
and calculated the area under the ROC curve (AUC).13,17 
Most researchers have now adopted AUC for evaluating 
predictive ability of classifiers owing to the fact that AUC 
is a better performance metric than accuracy.19 The AUC of 
Clinical factors  MFNN
Clinical factors  Wrapper-based
feature selection
Logistic 
regression
Wrapper-based
feature selection
Figure 1 in the wrapper-based feature selection approach, clinical factors are evaluated independently of the classification algorithms, such as multilayer feedforward neural 
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a   classifier can be interpreted as the probability that the clas-
sifier will rank a randomly chosen positive example higher 
than a randomly chosen negative one.19 The higher the AUC, 
the better the learner.20 In this study, AUC was used as a 
value to compare the performance of different prediction 
models on a dataset.
Results
Table 1 summarizes the results of repeated 10-fold cross-
validation experiments using the MFNN algorithm and 
logistic regression with the wrapper-based feature selection 
method. First, the input-output training data pairs were used 
to train the MFNN models. There were 24 genetic factors, 
that is, 24 SNPs. Using this information, the MFNN models 
were trained with 1-4 hidden layers using the wrapper-
based feature selection method. These trained MFNNs 
approximate the model of the responsiveness of IFN-alfa/
RBV among CHC patients. After the networks were trained, 
we used the trained networks to find the responsiveness 
condition corresponding to the testing set with the 10-fold 
cross-validation method. We calculated accuracy and AUC 
for the 10-fold cross-validation experiments. As indicated 
in Table 1, the average values of accuracy for the MFNN 
prediction models with 1-4 layers were 80.4%, 80.4%, 
80.0%, and 79.7%, respectively. Of all the MFNN models, 
MFNN with one layer and MFNN with two layers per-
formed best, outperforming the other two MFNN models 
in terms of accuracy and AUC. For the MFNN models with 
the wrapper-based approach, only 4 factors out of 24 were 
identified.
Next, we employed logistic regression with the wrapper-
based approach for comparisons. As shown in Table 1, the 
average value of accuracy for the logistic regression predic-
tion model with the wrapper-based approach was 75.3%. 
Among all five predictive models, the MFNN models 
were superior to the logistic regression model in terms of 
  accuracy. In addition, MFNN with one layer and MFNN 
with two layers were better than logistic regression in terms 
of AUC.   Moreover, logistic regression with the wrapper-
based approach selected 5 out of 24 factors.
Finally, the performance of logistic regression with the 
same four factors as the selected MFNN was at an accuracy 
of 72.1% and an AUC of 0.67, respectively.
Discussion
To the best of our knowledge, this is the first study that 
proposes the use of MFNN and logistic regression with the 
wrapper-based feature selection method to model the drug 
responding status in CHC patients using genetic factors. We 
developed a pharmacogenomics methodology to predict the 
drug efficacy of IFN-alfa/RBV in CHC patients based on 
genetic factors such as SNPs. Our results demonstrated that a 
trained MFNN model is a promising method for providing the 
inference from genetic factors, such as SNPs, to the respon-
siveness of IFN-alfa/RBV . Our findings suggest that our tool 
may provide the medical reference prior to treatment based on 
the information of genetic factors such as SNP genotypes.
A similar study by Lin and colleagues4 has been reported 
to utilize the MFNN algorithms to evaluate the possible 
nonlinear interactions between IFN-alfa/RBV response and 
factors such as seven SNPs, viral genotype, viral load, age, 
and gender. The same cohort of 523 patients with CHC was 
used in their and our studies. They reported that an MFNN 
network with one hidden layer had an accuracy of 77.4%.4 
The difference between our study and theirs was that in the 
present study we used 24 SNPs instead of only seven poly-
morphisms. Moreover, the wrapper-based feature selection 
method was not utilized in the previous study. As shown in our 
simulation results, our MFNN prediction model performed 
better than theirs in terms of accuracy. These preliminary 
results suggest that an MFNN model may be considered 
as a good method to deal with the complex nonlinear rela-
tionship between clinical factors and the responsiveness of 
IFN-alfa/RBV .
In the wrapper-based approach, no knowledge of the 
classification algorithm is needed for the feature selection 
Table 1 The results of repeated 10-fold cross-validation experiments using multilayer feedforward neural network (MFnn) and 
logistic regression with the wrapper-based feature selection method
Algorithm Accuracy (%) Accuracy, 95%  
confidence interval (%)
AUC AUC, 95%  
confidence interval (%)
Number of   
factors
MFnn with 1 hidden layer 80.4 79.4, 81.4 0.72 0.71, 0.73 4
MFnn with 2 hidden layers 80.4 79.4, 81.4 0.72 0.71, 0.73 4
MFnn with 3 hidden layers 80.0 79.0, 81.0 0.66 0.65, 0.67 4
MFnn with 4 hidden layers 79.7 78.7, 80.7 0.68 0.67, 0.69 4
Logistic regression 75.30 74.2, 76.3 0.69 0.68, 0.71 5
Abbreviation: AUC, the area under the receiver operating characteristic curve.Advances and Applications in Bioinformatics and Chemistry 2010:3 submit your manuscript | www.dovepress.com
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process, which finds optimal features by using the 
  classification algorithm as part of the evaluation function.17,18 
In addition, the wrapper-based method has the advantage 
that it includes the interaction between feature subset search 
and the classification model.17 However, the wrapper-based 
method may have a risk of over-fitting.17,21 In a recent study, 
Huang and colleagues applied three classification algorithms 
including naive Bayes, the support vector machine algorithm, 
and the C4.5 decision tree algorithm with two feature selec-
tion methods to identify a subset of influential SNPs.17 They 
utilized the wrapper-based feature selection method and the 
hybrid feature selection approach combining the chi-squared 
and information-gain methods. Their results suggested that 
the naive Bayes model with the wrapper-based approach 
performed maximally among predictive models to infer the 
disease susceptibility dealing with the complex relationship 
between chronic fatigue syndrome and SNPs.17
The MFNN and logistic regression models are currently 
the most widely used pattern recognition techniques. In this 
study, our MFNN model achieved a higher successful rate 
of prediction than the traditional logistic regression model. 
Unlike logistic regression, MFNN has the ability to model 
the multidimensional and nonlinear relationships between the 
variables as found in complex medical applications.22,24 More-
over, the MFNN algorithms demonstrate robust   performance 
in dealing with noisy or incomplete data.22,24 It is difficult to 
interpret individual variables generated by the MFNN, while 
logistic regression analysis provides insightful information 
for the interpretation of model parameters.14,23 Therefore, 
logistic regression can be used as a complementary method 
to the MFNN approach.22
In this study, we found that the MFNN model with two 
layers performed the same as the MFNN with one hidden layer 
in terms of accuracy and AUC. It has been demonstrated that 
the MFNN with only one hidden layer should be adequate as 
a universal approximator of any nonlinear function, indicating 
that the MFNN with one hidden layer is always enough.4,25 
Thus, this implication was validated by our simulation results 
in the present study. When an approximation with one hidden 
layer would require an impractically large number of hidden 
units in solving some complex real world problems, multiple 
hidden layers may become necessary.4,26,27
Further direct experimentation is warranted to evaluate 
the impact of the proposed approach on patient outcomes in 
the context of computerized clinical decision support systems 
(CDSSs), which are information systems designed to aid 
clinicians in making clinical decisions.28 In general, CDSSs 
provide clinicians with information systems for   diagnosis, 
prevention, and disease management, as well as for drug 
dosing and drug prescribing,28 and CDSSs have shown great 
promise for reducing practice errors, improving patient 
care, and achieving lower costs.29 Furthermore, CDSSs 
are probably best introduced into healthcare organizations 
in two stages, basic stage (such as drug-allergy checking, 
basic dosing guidance, and drug-drug interaction checking) 
and advanced stage (including dosing support for geriatric 
patients, guidance for medication-related laboratory testing, 
and drug-pregnancy checking).30 In addition, Kawamoto 
and colleagues identified several features strongly associ-
ated with a CDSS’s ability to improve clinical practice and 
  suggested that the automatic provision of decision support 
as part of clinician workflow is the most important feature 
(p , 0.00001).29 This finding is consistent with one of the 
Ten Commandments for effective CDSSs published by 
Bates and colleagues, that is, implementing CDSSs should 
fit into the user’s work flow and integrate suggestions with 
clinical practice.31
There were several limitations to this study as follows. 
First, the small size of the sample does not allow definite 
conclusions to be drawn. In addition, the contributions of 
other genetic markers as well as demographic and clinical 
factors should be further examined. It would seem that SNPs 
are inadequate as the only variable. Other data, especially 
from the clinical records and laboratory values of patients, 
could be included to improve model performance as a further 
development of the method. In future work, large prospective 
clinical trials are necessary in order to answer whether these 
genetic and clinical factors are reproducibly associated with 
IFN-alfa/RBV treatment response.
Conclusions
In this study, we developed an ANN methodology with the 
wrapper-based feature selection method to predict the drug 
efficacy of IFN-alfa/RBV in CHC patients based on clinical 
factors such as SNPs. We demonstrated that a trained MFNN 
model is a promising method for providing the inference from 
genetic factors to the responsiveness of IFN-alfa/RBV .
Our findings suggested that our tool may allow patients 
and doctors to make more informed decisions based on 
clinical factors such as SNP genotyping data. Over the next 
few years, genetic tests for the pretreatment prediction may 
become a reality in patient care after prospective large clini-
cal trials to validate clinical factors and genetic markers.4,5 
It may also provide potential drug targets for the development 
of alternative therapeutic agents to treat CHC patients, 
  especially for those NRs.4,5Advances and Applications in Bioinformatics and Chemistry
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